New relationships, risks, and business structures are redefining the marketplace. Learn what’s working, and what isn’t, in the race toward value.
Drug companies must join providers, payers, and patients in seeing themselves as stakeholders.
By now, it’s almost old news: big data will transform medicine. It’s essential to remember, however, that data by themselves are useless.
Using patient stratification and more primary care visits, Chicago-based Oak Street Health aims to reduce hospitalizations.
How can we better integrate mental and physical health services?
Join us November 2, 2017, as we kick off Navigating Payment Reform for Payers, Providers, and Pharma.
What would indication-based drug pricing accomplish?
The threat to individual market stability is real. We need to fix it before it's too late.
In the face of major pharmaceutical price increases, Cleveland Clinic developed a strategy to ensure high-quality patient care while maintaining financial stability.
Both political parties should support policies that focus on incentives as a mechanism for improving and sustaining their value.
Poor measures of care quality have consequences. The National Quality Forum is essential to creating measures that are valid and reliable.
The loss of CSR payments would create some short term chaos in the market, but it would not significantly impact the number of people covered.
Two veterans of public service say that government can do only so much — which creates attractive business opportunities for entrepreneurs.
A weekly email newsletter featuring the latest actionable ideas and practical innovations from NEJM Catalyst.